Behandlingen bør reserveres patienter for hvem, det betragtes som særdeles vigtigt at undgå homolog blodtransfusion, idet man vurderer fordele/ ulemper ved homolog blodtransfusion.
Treatment should be reserved for patients in whom it is considered of particular importance to avoid homologous blood transfusion taking into consideration the risk/ benefit assessment for homologous transfusions.